Results 111 to 120 of about 20,060 (180)

Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver. [PDF]

Viruses
Bao H, Murakami S, Tsuge M, Uchida T, Uchikawa S, Fujino H, Ono A, Murakami E, Kawaoka T, Miki D, Hayes CN, Oka S.   +11 more
europepmc   +1 more source

Functional cure of a young child with chronic hepatitis B cirrhosis treated by pegylated interferon α combination therapy: A case report. [PDF]

Medicine (Baltimore)
Gan Y, Zhang H.
europepmc   +1 more source

The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment. [PDF]

Virol J
Zhang W, Chen J, Sun W, Xie N, Tian F, Ruan Q, Song J.   +6 more
europepmc   +1 more source

Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera. [PDF]

Blood Adv
Sørensen AL, Skov V, Kjær L, Bjørn ME, Eickhardt-Dalbøge CS, Larsen MK, Nielsen CH, Thomsen C, Rahbek Gjerdrum LM, Knudsen TA, Ellervik C, Overgaard UM, Andersen CL, Hasselbalch H.   +13 more
europepmc   +1 more source

Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks. [PDF]

Hepatol Int
Tan Z, Kong N, Zhang Q, Gao X, Shang J, Geng J, You R, Wang T, Guo Y, Wu X, Zhang W, Qu L, Zhang F.   +12 more
europepmc   +1 more source

A predictive model for functional cure in chronic HBV patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data. [PDF]

Virol J
Ye YM, Lin Y, Sun F, Yang WY, Zhou L, Lin C, Pan C.   +6 more
europepmc   +1 more source

Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-α-2b-based therapy: a multicenter pilot study. [PDF]

Virol J
Chang LJ, Hao CQ, Rao GR, Xu LL, Li J, Cheng Y, Zheng LJ, Wu CW, Chen HX, Chen ZR, Lian JQ, Wu SH, Luo LM, Zhang WL, Zhang Y.   +14 more
europepmc   +1 more source

Predicting clinical outcomes in chronic hepatitis B patients receiving nucleoside analogues and pegylated interferon alpha: a hematochemical and clinical analysis. [PDF]

BMC Infect Dis
Xu S, Ye XT, Zhang D, Dong P, Wu YH, Pan CW.   +5 more
europepmc   +1 more source

Results of Response-Guided Therapy with Pegylated Interferon Alpha 2a in Chronic Hepatitis B and D. [PDF]

Trop Med Infect Dis
Gherlan GS, Lazar SD, Culinescu A, Smadu D, Vatafu AR, Popescu CP, Florescu SA, Ceausu E, Calistru PI.   +8 more
europepmc   +1 more source

Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study. [PDF]

Front Med (Lausanne)
Wang Z, Wang X, Zhou L, Shi S, Hua Y, Feng Y.   +5 more
europepmc   +1 more source